AEMETIS, INC
For the period ended Dec 31, 2024. Filed Mar 14, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 14, 2025
AMTX$1.59-8.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
(In thousands)
| Years ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating activities: | ||
| Net loss | $(87,537) | $(46,420) |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | ||
| Share-based compensation | 8,314 | 7,660 |
| Depreciation | 8,341 | 6,933 |
| Debt related fees and amortization expense | 6,463 | 6,524 |
| Intangibles and other amortization expense | 46 | 72 |
| Accretion and other expenses of Series A preferred units | 12,698 | 25,313 |
| Loss on asset disposals | 3,702 | - |
| Warrants issued for working capital agreement | - | 409 |
| Gain on debt extinguishment | (162) | - |
| Deferred tax (benefit) expense | - | (750) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 6,754 | (7,422) |
| Inventories | (7,766) | (13,843) |
| Prepaid expenses | 1,533 | 1,838 |
| Tax credit sale receivable | (12,300) | - |
| Other assets | (2,839) | (2,016) |
| Accounts payable | (1,294) | 13,726 |
| Accrued interest expense and fees, net of interest paid | 27,910 | 23,558 |
| Other liabilities | 3,208 | (1,757) |
| Net cash provided by (used in) operating activities | (32,929) | 13,825 |
| Investing activities: | ||
| Capital expenditures | (20,254) | (33,119) |
| Grant proceeds received for capital expenditures | 6,105 | 9,432 |
| Net cash used in investing activities | (14,149) | (23,687) |
| Financing activities: | ||
| Proceeds from borrowings | 19,461 | 75,482 |
| Repayments of borrowings | (5,010) | (56,130) |
| Lender debt renewal and waiver fee payments | (1,441) | (1,681) |
| Payments on Series A preferred financing | - | (30,000) |
| Payments on finance leases | (179) | (428) |
| Proceeds from sale of common stock | 31,750 | 21,718 |
| Proceeds from the exercise of stock options | 36 | 133 |
| Net cash provided by financing activities | 44,617 | 9,094 |
| Effect of exchange rate changes on cash and cash equivalents and restricted cash | 12 | 49 |
| Net change in cash and cash equivalents and restricted cash for period | (2,449) | (719) |
| Cash, cash equivalents, and restricted cash at beginning of period | 6,280 | 6,999 |
| Cash, cash equivalents, and restricted cash at end of period | 3,831 | 6,280 |
| Supplemental disclosures of cash flow information, cash paid: | ||
| Cash paid for interest | $9,223 | $9,813 |
| Income taxes paid | 1,814 | 20 |
| Supplemental disclosures of cash flow information, non-cash transactions: | ||
| Settlement of AP via issuance of RSAs | 265 | - |
| Subordinated debt extension fees added to debt | 680 | 680 |
| Fair value of warrants issued to subordinated debt holders | 916 | 1,278 |
| Fair value of warrants issued to lender for debt issuance costs | - | 318 |
| Lender debt extension, waiver, and other fees added to debt | 695 | - |
| Cumulative capital expenditures in accounts payable | 11,152 | 7,900 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.